Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data

BMO Capital Reiterates Outperform Rating on Amgen (AMGN)

November 12, 2024 4:24 PM EST

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $362.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "When has three patients worth of data ever been the 'be all and end all'? Context matters, and while this MariTide data... More

Barclays Reiterates Equalweight Rating on Amgen (AMGN)

November 12, 2024 4:23 PM EST

Barclays analyst Carter Gould reiterated an Equalweight rating and $315.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "We reviewed the supplemental MariTide (AMG133) phase 1 data, highlighted by (1) BMD loss (as measured by DEXA scan across femur and hip) at higher doses (420mg), and (2) notable heart rate excursions (25bpm at the 280mg dose). While far from... More

Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'

November 12, 2024 3:44 PM EST

Jefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "We reviewed public data from Phase I AMG-133 showing add'l measurements of BMD (bone density) from obesity pts - which could be interpreted... More

Amgen (AMGN) Quickly Falls to Low, Down Over 4% on Obesity Data Concerns

November 12, 2024 2:19 PM EST

(Updated - November 12, 2024 2:30 PM EST)

(Updated - November 12, 2024 2:21 PM EST)

Amgen (NASDAQ: AMGN) Quickly Falls to Low, Down Over 4%

Weakness appears to be related to concerns about its developmental weight loss... More

Amgen (AMGN): Tezspire Met Both Co-primary Endpoints In Phase 3 Trial For Chronic Rhinosinusitis With Nasal Polyps

November 8, 2024 7:06 AM EST

Amgen (NASDAQ: AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the known profile of the medicine.

WAYPOINT was a randomized, double-blind, placebo-controlled trial evaluating the... More